An Unusually Short Latent Period of Therapy-Related Myeloid Neoplasm Harboring a Rare MLL-EP300 Rearrangement: Case Report and Literature Review

Table 1

A summary of cases of therapy-related MLL-EP300-positive leukemia (cases 1–4).

Case	Age/sex	Phenotype	Karyotype	MLL-EP300 breakpoint	Latent period (months)	Primary malignancy	Cytotoxic exposure	Reference
1	4/M	AML	48,XY, +8, +8, t(11;22)(q23;q13)	MLLexon9/EP300exon15	67	NHL	Chemo including ETP	[16]
2	5/F	AML	46,XX, t(1;22;11)(q44;q13;q23), t(10;17)(q22;q21)	MLLexon7/EP300exon15	36	Neuroblastoma	Chemo including THP,	[17]
3	66/M	AML	46,XY, t(11;22)(q23;q13). idem, +8	MLLexon10, 11/EP300exon13	16	PTCL NOS, AML with MDS	CBDCA, CPA CHOP-14, ESHAP	[18]
4	62/F	CMML	46,XX, t(11;22)(q23;q13)	MLLexon10/EP300exon15	10	ATL	mLSG+ mogamulizumab	Present case

CHOP-14 contains cyclophosphamide, doxorubicin, vincristine, and prednisolone. ESHAP consists of etoposide, methylprednisolone, cytarabine, and cisplatin. ETP, etoposide; THP, pirarubicin; CBDCA, carboplatin; CPA, cyclophosphamide. mLSG contains VCAP (vincristine, cyclophosphamide, doxorubicin, and prednisone), AMP (doxorubicin, ranimustine, and prednisone), and VECP (vindesine, etoposide, carboplatin, and prednisone). NHL, non-Hodgkin lymphoma; PTCL NOS, peripheral T-cell lymphoma not otherwise specified; ATL, adult T-cell leukemia/lymphoma.